Le Lézard
Classified in: Health
Subject: FDA

FDA Clears SIG Medical's AdvantageRib Anterior System


HERSHEY, Pa., Nov. 19, 2018 /PRNewswire/ -- SIG Medical (www.sigmedical.net) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its AdvantageRib Anterior System, K182179. This product is the second rib fracture system that SIG Medical is commercializing.  SIG Medical is now the market leader in offering the most comprehensive portfolio of rib fracture products that are revolutionizing traditional care which left patients immobilized and in pain for months

AdvantageRib, the only intrathoracic and anterior plating system on the market: Your Patient.  Your Choice.

The comprehensive AdvantageRib Anterior System contains titanium plates and screws to treat rib fractures through a traditional anterior approach.  The system features anatomically contoured plates designed to fit patient anatomy, with geometry based on state-of-the-art scientific studies.  The system also has highly adaptable straight plates allowing the surgeon to create a construct to fit even the most challenging clinical scenarios.  The titanium screws available in the system consist of self-drilling, self-tapping, locking, non-locking, and a length range for all sizes of rib anatomy.  The intuitive instrumentation in the set allows for quick implantation while minimizing soft tissue dissection. The AdvantageRib Anterior System is intended for the fixation, stabilization, and fusion of rib fractures and osteotomies of normal and osteoporotic bone.

"We are thrilled to have achieved this approval and now have the most comprehensive portfolio of rib fracture products," said Andrew Davison, VP of Product Development and Marketing at SIG Medical.  "The AdvantageRib family of products is truly revolutionary and will change how suffering patients are treated.  Surgeons now have choices as to how best to treat their patients, in both a traditional manner or with our novel system that is on the forefront of improving how rib fractures are managed.  Today is a huge leap for us and the medical community as a whole."

This approval comes just weeks after SIG Medical announced that it closed its oversubscribed Series Seed funding round.  "We have a world class team, working capital, and now the most complete line of products to lead the market in fixing fractured ribs," said Ken Kremer, President and CEO of SIG Medical.  "The AdvantageRib family of products will have a significant impact on the algorithm of care for decades to come and I am proud to be part of such an exciting movement."

About SIG Medical

SIG Medical is pioneering rib fixation optimized for the operating room. Our mission is to provide more immediate and definitive patient care: reducing pneumonia, time in intensive care, chronic pain, ventilator support, chest wall deformity, and accelerate patient recovery.  We aim to improve patient care and significantly reduce the overall cost to the healthcare system. For more information, visit www.sigmedical.net

More Info:
Andrew Davison, Vice-President
SIG Medical
717-756-3139
[email protected]

SIG Medical Logo (PRNewsfoto/SIG Medical)

SOURCE SIG Medical


These press releases may also interest you

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...



News published on and distributed by: